NeuroSense Therapeutics Ltd.
NRSNNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $3.14M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.63$19.00
- Volume (live)
- -
- Avg. volume (3M)
- 24.78K
NeuroSense Therapeutics (NRSN) Stock Price & Financial Analysis
NeuroSense Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.40 - $2.55 |
|---|---|
| 52-Week High | $19.00 |
| 52-Week Low | $0.63 |
| Open | $2.49 |
| Volume (last close) | 11.07K |
| Average Volume (3M) | 24.78K |
| 50-Day MA | $6.43 |
|---|---|
| 200-Day MA | $4.57 |
| 1-Year Change | +110.34% |
| Market Cap | 3.14M |
|---|---|
| Shares Outstanding | 1.28M |
| Price to Book (P/B) | -2.02 |
| EV/EBITDA | -0.26 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
NeuroSense Therapeutics at a Glance
As of the Oct 23, 2026 close, NeuroSense Therapeutics (NRSN) has a market capitalization of $3.14M.
As of its latest reported balance sheet, it holds $166.00K in cash and securities against $170.00K of debt, a net debt position of $4.00K.
NeuroSense Therapeutics does not currently pay a dividend.
The share price is up 110.3% over the past year. At $2.46 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $0.63 to $19.00, below its 200-day moving average of $4.57.
Frequently Asked Questions About NeuroSense Therapeutics
What is the current stock price for NRSN?
As of the Oct 23, 2026 close, NRSN stock trades at $2.46. The 52-week range is $0.63–$19.00, with a day range of $2.40–$2.55.
What is the P/E ratio for NRSN?
The P/E ratio (Price-to-Earnings) for NRSN is shown in the Key Statistics section. This valuation metric helps compare NeuroSense Therapeutics Ltd. to industry peers.
Does NRSN pay dividends?
NeuroSense Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for NRSN?
Analyst ratings and recommendations for NRSN are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of NRSN?
As of the Oct 23, 2026 close, NeuroSense Therapeutics's market capitalization is $3.1M, classifying it as a micro-cap company. NeuroSense Therapeutics operates in the Healthcare sector within the Biotechnology industry.